Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763798 | 0.81 | TSHR (0.40) | TSHRMEN1KMT2AUSP2ABCB11 | |
| SCHEMBL12761589 | 0.79 | TSHR (0.39) | TSHRMEN1KMT2AUSP2ABCB11 | |
| SCHEMBL13667756 | 0.79 | TSHR (0.39) | TSHRMEN1KMT2AUSP2ABCB11 | |
| SCHEMBL6280144 | 0.77 | DGAT1 (0.42) | PKM | |
| SCHEMBL19591877 | 0.76 | TSHR (0.36) | TSHRMEN1KMT2AUSP2ABCB11 | |
| SCHEMBL18924771 | 0.74 | TSHR (0.39) | TSHRMAPTMAPK1SMN1; SMN2PKM | |
| SCHEMBL2478389 | 0.74 | TSHR (0.48) | TSHRMEN1KMT2AUSP2ABCB11 | |
| SCHEMBL6063978 | 0.74 | TSHR (0.48) | TSHRMEN1KMT2AUSP2ABCB11 | |
| SCHEMBL15105841 | 0.73 | DGAT1 (0.50) | TDP1PKM | |
| SCHEMBL18583841 | 0.73 | TSHR (0.33) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | MIRACURE BIOTECHNOLOGY LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | MIRACURE BIOTECHNOLOGY LTD (CN) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | PNP, MTAP, TYMP | TSHR 4041/4885MEN1 3376/4885KMT2A 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.